AliveCor offers NICE-Recommended Personal ECG To Support Remote Cardiac Care Services

KardiaMobile would be prescribed by a healthcare professional for people experiencing arrhythmia

By
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

 AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, announced that the National Institute for Health and Care Excellence (NICE) has issued medical technologies guidance (MTG) recommending KardiaMobile as an option for detecting atrial fibrillation (AF) for people with suspected paroxysmal AF.

Company handle

KardiaMobile would be prescribed by a healthcare professional for people experiencing arrhythmia (irregular heart rhythm) symptoms more than 24 hours apart. The instructions for use state that all interpretations of ECG recordings are reviewed by a healthcare professional and used to support clinical decision making, said a statement.

 "AliveCor is proud to be able to offer the only NICE-recommended personal ECG to support remote cardiac care services for patients not in front of their cardiologist. Today's recommendation not only highlights the clinical superiority of KardiaMobile against the current standard of care, but also its position as a more cost-effective solution, therefore warranting its value as a clinical tool to support rapid diagnosis of AF,” said Priya Abani, CEO of AliveCor.

AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically-validated personal ECG solution in the world. Kardia is the first AI-enabled platform to aid patients and clinicians in the early detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor's enterprise platform allows third party providers to manage their patients' and customers' heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, added the statement.